3 Large-Cap Stocks Trading at a Discount

NASDAQ: INTC | Intel Corporation News, Ratings, and Charts

INTC – With high hopes for a fast-paced recovery of the U.S. economy, market sentiment is upbeat. However, volatility and inflationary headwinds cannot be ruled out in the near term given the resurgence in COVID-19 cases around the world. Hence, we think it advisable to bet on fundamentally sound large-cap stocks, namely Intel (INTC), Sanofi (SNY), and GlaxoSmithKline (GSK). They are trading at discounts to their peers. And in addition to offering stability, these stocks may deliver decent upside in the near term. Read on.

The U.S. economy is braced for a fast-paced recovery thanks to the federal recovery spending and a mass COVID-19 inoculation drive. However, concerns about inflation and sudden volatility continue to lurk in the wings. The resurgence of COVID-19  infections worldwide, in particular, could inject volatility into the markets in the coming months.

Against this backdrop, investors must be  judicious in picking stocks and protect their portfolios against negative events. The Financial Times recently quoted Senior global macro strategist at State Street, Marvin Loh. He said, “A lot of the good news is built-in . . . but I do see the potential for [investors] to continue to bid up risky assets, just because there is so much liquidity and it remains a supportive environment.”

We believe fundamentally sound large-cap stocks are perfect bets at this point. Historically, behemoths like Intel Corporation (INTC), Sanofi (SNY), and GlaxoSmithKline Plc (GSK) have remained resilient during times of heightened volatility and helped investors to sail through adversities with stable returns.  Also, these three stocks are currently trading discounts to their peers, offering solid upside potential.

Intel Corporation (INTC)

INTC is a global chipmaker that develops and markets solutions for the cloud, smart, and connected devices for retail, industrial, and consumer uses. The company operates through DCG, IOTG, Mobileye, NSG, PSG, CCG segments.

INTC plans to spend $20 billion to construct two factories in Arizona, and it will also open its factories to external customers. The chipmaker aims to tackle issues related to manufacturing delays with this initiative. INTC also wants to fight Taiwan’s dominance in global chip manufacturing.

INTC’s revenue for the fourth quarter, ended December 31, 2020, declined 1% year-over-year to $20 billion. Its EPS for the quarter fell  to $1.42 from $1.58 posted in the prior year period. INTC’s data-centric business unit’s revenue declined 11% year-over-year, while its PC-centric business revenue rose 9% to $10.9 billion.

Analysts expect INTC’s revenue for the quarter ending March 31, 2021 to be $17.9 billion, representing a 9.8% year-over-year decline. Its EPS is likely to grow at the rate of 5.4% per annum over the next five years.

INTC has gained 30% on a year-to-date basis to close yesterday’s trading session at $66.54. Over the past six months, the stock has gained 24.9%. In terms of forward ev/sales, INTC is currently trading at 3.76x, 12.8% lower than the industry average  4.31x. The stock’s forward price/earnings of 14.97x is also 53.2% lower than the industry average  32x.

INTC’s strong fundamentals are reflected in its POWR Ratings. The stock has an overall rating of B, which equates to Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors with each factor weighted to an optimal degree.

INTC has an A grade for Value and Quality, and a B grade for Sentiment and Momentum. Of the 98 stocks in the B-rated Semiconductor & Wireless Chip industry, it is ranked #8.

In addition to the POWR Ratings grades we’ve just highlighted, one  can see INTC ratings for Growth and Stability, here.

Sanofi – ADR (SNY)

SNY is a French pharmaceutical company that researches, develops, manufactures, and markets various therapeutic solutions. Pharmaceuticals, Vaccines, and Animal Health are the three segments through which the company operates.

SNY plans to build a new flu vaccine center in Canada for nearly $700 million. This facility will be situated in Toronto and will boost the supply of influenza vaccines in Canada, the U.S. and Europe.

During the fourth quarter, ended December 31, 2020, SNY’s revenue declined 2.4% year-over-year to Euro 9.3 billion. However, its  Vaccine-related revenue climbed 8% over the year to Euro 2 billion, as distinguished influenza vaccines witnessed strong demand. The company has also revealed its intention to help PFE and BioNTech  manufacture 125 million doses of their COVID-19 vaccine. Dupixent was the only product that witnessed  good growth during the quarter.

A consensus revenue estimate for the quarter ending March 31, 2021 is $10.2 billion, representing a 3.3% year-over-year growth. Its EPS is expected to grow at the rate of 7.5% per annum over the next five years.

SNY ended yesterday’s trading session at $50.18, gaining 10% over the past year. SNY is an appealing value stock. In terms of forward ev/ebitda, SNY is currently trading at 9.65x, 42.9% lower than the industry average  16.9x. The stock’s forward price/earnings of 12.59x is also 57.1% lower than the industry average of 29.39x.

Due to its bright prospects, SNY has an overall B rating, which translates to a Buy in our POWR Rating system. SNY has a Stability and Value Grade of A. In the Medical – Pharmaceuticals industry, it is ranked #30 of 237 stocks.

Click here to see the additional POWR Ratings for SNY (Growth, Sentiment, Quality, and Momentum).

Click here to checkout our Healthcare Sector Report for 2021

GlaxoSmithKline Plc (GSK)

GSK is a global healthcare leader that discovers, develops, manufactures, and markets pharmaceutical products, over-the-counter medicines, vaccines, and other consumer health products in the U.S., U.K., and other countries. Pharmaceuticals, pharmaceuticals R&D, vaccines, and consumer healthcare are the four segments through which it operates.

GSK’s board of directors has approved the sale of its manufacturing facility in Vemgal, India to Hetero Labs of India for $25 million. GSK had purchased this facility for $155 million.

During the fourth quarter, ended December 31, 2020, GSK’s turnover climbed 1% year-over-year to GBP34 billion. Its EPS for the quarter rose to 115.5 pence from 93.9 pence posted in the prior year period.

Analysts expect GSK’s revenue for the quarter ending March 31, 2021 to be $11.9 billion, representing  a 2% increase year-over-year. Meanwhile, its EPS is likely to increase at the rate of 4.7% per annum for the next five years.

Year-to-date, GSK has declined3.6% to end yesterday’s trading session at $36.08. Over the past six months, the stock has retreated  5%.

GSK is one of the best value stocks in the healthcare space currently . In terms of forward ev/sales, GSK is currently trading at 2.67x, 61.1% lower than the industry average  6.85x. The stock’s forward price/earnings of 9.06x is also 57.1% lower than the industry average  21.12x.

GSK’s strong fundamentals are reflected in its POWR Ratings. The stock has an overall B rating, which equates to Buy in our proprietary rating system. GSK has an A Grade for Value, and a B Grade for Quality and Stability. In the Medical – Pharmaceuticals industry, it is ranked #23.

Click here to checkout our Healthcare Sector Report for 2021

Want More Great Investing Ideas?

“MUST OWN” Growth Stocks for 2021

How to Ride the NEW Stock Bubble?

5 WINNING Stocks Chart Patterns

Unlock the POWR in Your Portfolio!

 


INTC shares were trading at $65.61 per share on Tuesday afternoon, down $0.93 (-1.40%). Year-to-date, INTC has gained 33.28%, versus a 9.13% rise in the benchmark S&P 500 index during the same period.


About the Author: Namrata Sen Chanda


Namrata is an accomplished financial journalist, with nearly a decade of experience. She specializes in interpreting news releases and framing investment strategies, and has worked with some of the leading companies in real estate, banking, insurance, mutual funds, financial research, fintech, and investment education. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
INTCGet RatingGet RatingGet Rating
SNYGet RatingGet RatingGet Rating
GSKGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


:  |  News, Ratings, and Charts

How to Beat the Market the Rest of the Year?

The easy gains that came at the start of this new bull market are fading away fast. In fact the stock market (SPY) has become quite volatile with gains harder to come by. Gladly there are solutions as will be shared in this commentary to get you on the right path to outperform the market through the end of 2021 and beyond. Read the rest below...

:  |  News, Ratings, and Charts

2022 Stock Market Outlook

The stock market (SPY) has continued on a bullish path in 2021. Will that continue in 2022? And what could happen to awaken the bear market from hibernation? 40 year investment veteran Steve Reitmeister explores this and more in this early edition of his 2022 Stock Market Outlook. Read on for full details below...

:  |  News, Ratings, and Charts

3 Cheap Healthcare Stocks to Buy Right Now

Healthcare stocks saw renewed interest due to the onset of the pandemic, but It’s not only COVID that is driving returns. The Baby Boomer generation is getting older, which is resulting in increased demand for healthcare products and services. That’s why investors should consider adding undervalued healthcare stocks such as Ironwood Pharmaceuticals, Inc. (IRWD), Nu Skin Enterprises, Inc. (NUS), and Bristol-Myers Squibb Co. (BMY) to their portfolio.

:  |  News, Ratings, and Charts

3 Value Stocks to Buy While You Still Can

After outperforming from last fall into the spring, value stocks have been overtaken by growth stocks, but that is expected to change as the economic recovery continues. So, now is the time to start putting your money to work in undervalued companies that offer the potential for strong returns such as Gilead Sciences Inc. (GILD), HP Inc. (HPQ), and CNH Industrial N.V. (CNHI).

:  |  News, Ratings, and Charts

3 Cheap Healthcare Stocks to Buy Right Now

Healthcare stocks saw renewed interest due to the onset of the pandemic, but It’s not only COVID that is driving returns. The Baby Boomer generation is getting older, which is resulting in increased demand for healthcare products and services. That’s why investors should consider adding undervalued healthcare stocks such as Ironwood Pharmaceuticals, Inc. (IRWD), Nu Skin Enterprises, Inc. (NUS), and Bristol-Myers Squibb Co. (BMY) to their portfolio.

Read More Stories

More Intel Corporation (INTC) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All INTC News